Senior Management

StarkAge Therapeutics is lead by a team with strong and experiences needed to navigate the early stage of the company.

Senior Management

Thierry MATHIEU, Chief Executive Officer

A medical doctor specialized in immunology, Dr. Mathieu participated in the creation, administration, management and transfer of the Synlab Biology Group (formerly known as Labco), of which he was Scientific Director. A successful serial entrepreneur, he has created several start-ups in the bio-technology and innovation sector.

Benjamin LE CALVÉ, Chief Scientific Officer

Benjamin obtained his PhD in 2011 at the Free University of Brussels. During his postdoctoral positions, he joined different research centers in Canada, France and Belgium to develop competences in the oncology and senescence fields. Recently, he was a member of the research and development department of a biopharmaceutical company specialized in immunotherapy.

Franck IBLED, Chief Financial Officer

An entrepreneur himself, Franck supports start-up leaders in their ascent to stability as strategic and financial consultant. He helps structure their administrative and financial structures and procedures and supports their fundraising efforts.


Eric Angevin, MD, PhD

Dr Eric Angevin, MD-PhD, is since 2006 in charge of the development of industrial partnerships and collaborations as Alliance Manager at the institutional level of Gustave Roussy Cancer Center (Villejuif, France). He has an extended background in clinical and translational research with specific interests in the development of monoclonal antibodies/ADCs, immunotherapies and precision medicine programs with an experience of more than 15 years as senior investigator at the Drug Development Department (DITEP) of Gustave Roussy recognized as one of the largest early clinical trials facility in Europe. Dr Angevin has been involved in more than three hundred clinical trials including “first-in-human” studies, and has been contributor to more than 100 articles (h-index 39) in peer-reviewed international journals. He is an active member of ASCO, AACR, ESMO and TAT communities.